Celgene Corporation (NASDAQ: CELG) today announced its presentation at Sanford C. Bernstein's 28th Annual Strategic Decisions Conference on Wednesday, May 30, 2012 at 3:00p.m. EST will be webcast live and will be available in the investor relations section of the Company's Web site at www.celgene.com. Celgene management will provide an overview of the Company.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.
Forward-Looking Statements
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
In addition to financial information prepared in accordance with U.S. GAAP, this press release also contains non-GAAP financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These non-GAAP measures should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items.Other companies may define these measures in different ways. Non-GAAP total revenue approximates GAAP total revenue for each of the periods presented. See the attached Reconciliations of GAAP to non-GAAP diluted earnings per share for explanations of the amounts excluded and included to arrive at non-GAAP diluted earnings per share amounts for the three-month and full year periods ended December 31, 2011 and for the projected amounts for the year ending December 31, 2012.
Contacts:
Celgene Corporation
Jacqualyn A. Fouse, Ph.D., 908-673-9956
Executive
Vice President and
Chief Financial Officer
or
Patrick E.
Flanigan III, 908-673-9969
Vice President
Investor Relations
